Eliquis (apixaban) carries a small but real risk of bleeding inside the eye, as do all blood thinners. The reassuring finding from large-scale research is that Eliquis and similar newer anticoagulants appear to cause less intraocular bleeding than the older standard, warfarin. Still, “lower risk” is not “no risk,” and anyone taking Eliquis long-term deserves a clear picture of what can go wrong with their eyes, what the warning signs look like, and when the risk climbs higher than usual.
Why Blood Thinners Can Affect the Eyes
The eye is one of the most densely vascularized organs in the body. The retina, the gel-filled vitreous cavity, the tissue under the conjunctiva, and the structures that drain fluid in glaucoma are all threaded with tiny blood vessels. When you take a medication like Eliquis that inhibits one of the clotting proteins (in this case, factor Xa), every blood vessel in your body becomes slightly more prone to leaking if it is damaged or stressed. Most of the time that tendency shows up as easy bruising on the skin or minor gum bleeding. Occasionally, though, it shows up in the eye, where even a small amount of blood can interfere with vision.
The eye’s vulnerability is partly mechanical. Coughing, straining, rubbing your eyes, or even a sudden spike in blood pressure can put enough force on delicate capillaries to cause a tiny bleed. In someone not on a blood thinner, the clotting system seals these micro-injuries almost instantly. In someone on Eliquis, the seal takes longer, and the bleed can spread a bit further before it stops. That is the basic trade-off behind all anticoagulant-related eye problems.
How Eliquis Compares to Warfarin for Eye Bleeding
The most useful data on this question comes from a systematic review and meta-analysis that pooled twelve randomized trials covering more than 100,000 patients. Patients assigned to newer oral anticoagulants (a group that includes Eliquis, rivaroxaban, dabigatran, and edoxaban) had roughly a 22% lower relative risk of intraocular bleeding compared with patients on warfarin. That reduction was consistent regardless of whether the patients were taking the drug for atrial fibrillation or for venous blood clots, and it held across the different newer anticoagulants without a significant difference among them.1PubMed Central. Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis
Why would newer drugs be gentler on the eyes than warfarin? One likely reason is that warfarin interferes with multiple clotting factors at once and its blood levels fluctuate widely depending on diet, other medications, and individual metabolism. Eliquis targets a single clotting factor and maintains more predictable drug levels, which means fewer episodes of being “too thin.” For the eye’s fragile vasculature, that stability matters.
This does not mean Eliquis is perfectly safe for the eyes. It means that switching from warfarin to Eliquis, or starting on Eliquis rather than warfarin, is unlikely to increase your eye-bleeding risk and may modestly lower it. If you are already on Eliquis and worried about your eyes, the comparison to warfarin is probably the most practically useful number to keep in mind.
How Often Intraocular Bleeding Actually Happens With Eliquis
Even within the newer anticoagulant category, Eliquis appears to sit at the lower end of reported eye-bleeding cases. An analysis of adverse-event reports submitted to the FDA found no statistically significant difference in ocular hemorrhage between apixaban and rivaroxaban.2PubMed Central. Apixaban- and Rivaroxaban-Associated Bleeding: A Retrospective Analysis Using the FDA Adverse Event Reporting System A separate study that compiled global adverse-event reports for all newer anticoagulants found a total of 156 cases of intraocular hemorrhage. Of those, 82 were linked to rivaroxaban, 65 to dabigatran, and only 9 to apixaban. The authors cautioned that the low number of apixaban cases made meaningful statistical comparison difficult.3PubMed Central. Risk of intraocular hemorrhage with new oral anticoagulants
There are a few reasons the apixaban count was so low. At the time the data were collected, Eliquis had been on the market for a shorter period than either rivaroxaban or dabigatran, so fewer patients had been exposed. Adverse-event databases also rely on voluntary reporting, which means the true number of cases is almost certainly higher for every drug in the class. What the numbers do suggest is that eye bleeding on Eliquis is uncommon in absolute terms and not conspicuously more common than on related drugs.
What Eye Bleeding Looks Like in Practice
Not all bleeding in the eye is created equal. The type that matters most depends on where the blood ends up, and the symptoms range from cosmetically alarming but harmless to genuinely vision-threatening.
- Subconjunctival hemorrhage: A bright red patch on the white of the eye. This is the most common and least dangerous form. It looks dramatic but is essentially a bruise on the eye’s surface. Vision is unaffected, and it resolves on its own within a week or two. People on Eliquis may notice these more often, especially after rubbing their eyes or straining.
- Hyphema: Blood in the front chamber of the eye, between the cornea and the iris. This can blur vision and raise eye pressure. It usually follows trauma but can occur spontaneously in someone on anticoagulants. It generally requires monitoring by an ophthalmologist.
- Vitreous hemorrhage: Bleeding into the gel that fills the main cavity of the eye. This can cause sudden floaters, a reddish tint to vision, or significant vision loss depending on severity. It is less common than surface bleeding but more clinically serious.
- Retinal hemorrhage: Bleeding on or within the retina itself. Depending on the location, a small retinal hemorrhage might cause no symptoms at all or might produce a blind spot. Larger bleeds can threaten central vision.
The adverse-event data mentioned above included reports of retinal and vitreous hemorrhage among apixaban users, though the numbers were too small to draw firm conclusions about how often these more serious types occur specifically with Eliquis.3PubMed Central. Risk of intraocular hemorrhage with new oral anticoagulants For most patients, the everyday concern is the benign surface bleed rather than deep intraocular bleeding.
Eye Surgery While Taking Eliquis
One of the most common practical questions for Eliquis users is whether to stop the drug before eye surgery. The answer depends heavily on what kind of procedure you are having.
For low-risk procedures like cataract surgery, many ophthalmologists now continue anticoagulants without interruption. Cataract surgery involves very small incisions and minimal manipulation of vascular tissue, so the bleeding risk from the surgery itself is low. Stopping Eliquis, on the other hand, briefly removes your protection against stroke or blood clots, which can be far more dangerous than a small operative bleed. The general trend in perioperative guidelines has been toward keeping patients on their anticoagulant for cataract surgery and similar low-risk procedures.4PubMed Central. Perioperative Management of Anticoagulants in Ocular Surgeries
High-risk eye surgeries are a different story. Glaucoma surgeries, particularly trabeculectomy, involve tissue that bleeds more easily and where post-operative bleeding can compromise the outcome. One study found that patients who remained on anticoagulation throughout glaucoma surgery had a hemorrhagic complication rate of about 32%, compared with significantly lower rates in patients who stopped treatment beforehand.5New Frontiers in Ophthalmology. The implications of novel oral anticoagulation in ocular surgery That is a substantial difference and explains why surgeons performing these procedures often ask patients to pause Eliquis for a few days before and after. Vitreoretinal surgery (operations on the retina or vitreous) falls into a similar high-risk category.
The decision to stop or continue always involves weighing your personal stroke or clot risk against the surgical bleeding risk, and it should be made jointly by your ophthalmologist and the doctor who prescribed Eliquis. Never stop Eliquis on your own before a procedure without discussing it with both providers.
When Aspirin or Other Drugs Increase the Danger
Some patients end up on both Eliquis and aspirin, particularly after a heart attack, a coronary stent placement, or when a doctor judges the combined clot-prevention benefit to outweigh the added bleeding risk. That combination measurably increases the chance of bleeding. A study of atrial fibrillation patients found that adding aspirin to an oral anticoagulant raised the risk of major bleeding by about 50% and similarly increased bleeding-related hospitalizations.6PubMed Central. Combined Aspirin and Anticoagulant Therapy in Patients with Atrial Fibrillation
That increased bleeding risk applies body-wide, including the eyes. If you take both Eliquis and aspirin, you are more likely to develop subconjunctival hemorrhages and potentially more serious intraocular bleeding than someone on Eliquis alone. Over-the-counter anti-inflammatory drugs like ibuprofen and naproxen also affect platelet function and can add to the risk, even though they are not prescribed as blood thinners. Fish oil supplements at high doses have a mild blood-thinning effect as well.
The practical takeaway is to make sure every doctor you see, including your eye doctor, knows the full list of medications and supplements you take. If you are on Eliquis plus aspirin and experiencing frequent red patches on your eyes, it is worth asking whether the aspirin is still necessary. In many cases, especially once a stent has had time to heal, doctors will drop the aspirin and keep the Eliquis alone, which reduces the overall bleeding burden without sacrificing stroke protection.
Signs That Warrant a Call to Your Eye Doctor
Knowing what to watch for saves unnecessary panic over harmless bleeds while ensuring you catch the rare serious one early. A bright red spot on the white of your eye that is painless and does not affect your vision is almost always a subconjunctival hemorrhage. It looks alarming but does not need emergency care. If you are getting them frequently, mention it at your next appointment, but there is no need to rush in.
Symptoms that do warrant a prompt call or visit include:
- Sudden new floaters: A shower of dark spots or cobweb-like shapes drifting across your vision, especially if they appear all at once.
- A dark curtain or shadow: A portion of your visual field going dark, as if a shade is being pulled down. This can indicate a retinal hemorrhage or detachment.
- Sudden blurry or reddish vision: If the world suddenly looks hazy or takes on a red or brown tint in one eye, blood may be leaking into the vitreous.
- Eye pain with redness: Pain alongside visible bleeding could indicate a hyphema or elevated eye pressure.
These symptoms do not necessarily mean Eliquis caused the problem. Many eye conditions (diabetic retinopathy, retinal vein occlusion, posterior vitreous detachment) can cause bleeding independently. But being on Eliquis may make a bleed larger or slower to resolve, so timely evaluation matters more than it would for someone not on an anticoagulant.
Conditions That Raise Your Baseline Eye-Bleeding Risk
Eliquis does not operate in a vacuum. Certain pre-existing eye and systemic conditions make intraocular bleeding more likely regardless of anticoagulant use, and Eliquis layers additional risk on top of that baseline.
Diabetic retinopathy is the most common example. Diabetes damages the small blood vessels of the retina over time, making them fragile and prone to leaking. A person with advanced diabetic retinopathy who also takes Eliquis has two independent reasons for retinal bleeding. Age-related macular degeneration (the “wet” form) involves abnormal, leaky new blood vessels growing under the retina, and those vessels are particularly susceptible to hemorrhage in the presence of anticoagulation. Retinal vein occlusion, where a clot blocks a vein draining the retina, can cause secondary hemorrhages that may be more extensive in someone on Eliquis.
If you have any of these conditions and are starting Eliquis, it is reasonable to ask your ophthalmologist about a monitoring schedule. More frequent dilated eye exams can catch bleeding earlier, when treatment options like laser therapy or anti-VEGF injections are most effective. The presence of one of these conditions does not mean you cannot take Eliquis, but it does mean your eyes deserve closer surveillance.
Fear of Bleeding and the Risk of Skipping Doses
Here is an irony worth addressing directly: some people become so worried about bleeding, including eye bleeding, that they start skipping doses of Eliquis or stop taking it altogether. That can be more dangerous than the bleeding they are trying to avoid. A cross-sectional survey of atrial fibrillation patients on apixaban found that fear of severe bleeding was one of the top reasons for poor adherence. Among patients with the worst adherence scores, about 39% cited worry about severe bleeding as a major factor. Almost half of all patients who were not taking their medication consistently had never told their doctor.7PubMed Central. Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban: A Cross-Sectional Survey of Atrial Fibrillation Patients
Skipping Eliquis doses raises your risk of stroke, and strokes themselves can cause catastrophic eye damage through retinal artery occlusion (which can permanently blind an eye in minutes). The drug’s half-life is relatively short, which means missed doses leave gaps in protection more quickly than with warfarin. If you are worried about bleeding, the right move is to talk to your prescriber about whether your dose is appropriate or whether a different strategy might work, not to quietly reduce your doses on your own.
Cost was also a major barrier to adherence in the same survey, with patients sometimes stretching their supply by taking fewer pills. If cost is a factor for you, manufacturer discount programs and generic apixaban (which became available in the United States in 2023) may help. Consistent dosing protects you far more than the small bleeding risks it entails.
Wet Macular Degeneration Injections and Eliquis
Millions of people receive regular intravitreal injections (shots directly into the eye) for wet age-related macular degeneration and other retinal conditions. These injections involve passing a needle through the sclera into the vitreous cavity, which naturally raises the question of whether being on Eliquis makes the procedure riskier.
The needle used is extremely thin, and most retinal specialists do not ask patients to stop anticoagulants before intravitreal injections. The most common complication is a subconjunctival hemorrhage at the injection site, which looks dramatic but resolves without treatment. Serious intraocular bleeding from the injection itself is rare even in anticoagulated patients. Given that the injections often need to happen every four to eight weeks, repeatedly stopping and restarting Eliquis would create dangerous gaps in anticoagulation. The consensus in retinal practice has moved firmly toward continuing Eliquis through injection cycles.
If you are receiving these injections and notice that the red patches on your eye after each visit are larger or more persistent than they used to be, it is worth mentioning to your retinal specialist. Occasionally, adjusting the injection technique or site can minimize surface bleeding. But a subconjunctival hemorrhage after an eye injection while on Eliquis is expected, not a sign that something has gone wrong.